EUVIMEDEUVIMED entdecken
Crossref

High-Purity Production of Endothelial Cells from Human Pluripotent Stem Cells

Koki Yoshimoto, Ririka Okaichi, Kei Iida, Shiho Terada, Ken-ichiro Kamei

Cell Therapy & Engineering Connect · 2025

DOI: 10.69709/ctec.2025.154455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Therapy & Engineering Connect, 2025. Verfasst von Koki Yoshimoto und 4 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Nakatani Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial cells (ECs) are essential for vascular network formation and tissue homeostasis, yet the fields of tissue engineering and vascularized organoid generation still rely heavily on human umbilical vein ECs (HUVECs), which are venous, allogeneic, and challenging to mature fully. Human pluripotent stem cells (hPSCs) offer an autologous, developmentally flexible alternative, but most differentiation protocols require fluorescence-activated cell sorting, limiting scalability. Here, we present a streamlined method that produces highly pure ECs directly from human embryonic stem cells (hESCs) without cell sorting. Extending Wnt pathway activation with CHIR99021 for three days maximizes mesoderm induction, while a brief Notch inhibition using DAPT during the specification phase suppresses smooth muscle cell commitment. The result is over 90% CD31+ CD144+ ECs that display classic cobblestone morphology, robust DiI-acetylated LDL uptake, and capillary-like sprouting comparable to HUVECs. Bulk RNA barcoding and sequencing segregates the hESC-derived ECs from both HUVECs and undifferentiated hESCs and uncovers an artery-enriched transcriptome: NOTCH1, DLL4, and CXCR4 are up-regulated, whereas venous markers (EPHB4, NRP2) are reduced. Enrichment of Notch-responsive pathways further supports an arterial-like identity. Although several adult functional genes (e.g., vWF, NOS3) are expressed at lower levels than in HUVECs, the protocol delivers a scalable source of developmentally relevant ECs ideal for vascularizing organoids derived from the same hPSCs and for future applications in drug screening, disease modeling, and cell-based vascular therapies.

Förderung

  • Japan Society for the Promotion of Science
  • Nakatani Foundation

Zitieren

APA

Yoshimoto, K., Okaichi, R., Iida, K., Terada, S., & Kamei, K. (2025). High-Purity Production of Endothelial Cells from Human Pluripotent Stem Cells. Cell Therapy & Engineering Connect. https://doi.org/10.69709/ctec.2025.154455

Vancouver

Yoshimoto K, Okaichi R, Iida K, Terada S, Kamei K. High-Purity Production of Endothelial Cells from Human Pluripotent Stem Cells. Cell Therapy & Engineering Connect. 2025. doi:10.69709/ctec.2025.154455

BibTeX
@article{Yoshimoto2025,
  author = {Yoshimoto, Koki and Okaichi, Ririka and Iida, Kei and Terada, Shiho and Kamei, Ken-ichiro},
  title = {High-Purity Production of Endothelial Cells from Human Pluripotent Stem Cells},
  journal = {Cell Therapy & Engineering Connect},
  year = {2025},
  doi = {10.69709/ctec.2025.154455}
}
Kostenlos starten →